

# ACR REVIEW 3-8 NOVIEMBRE 2017 SANDIEGO

ACR-REVIEW.SER.ES



Sociedad Española de  
Reumatología

*Lilly*

**ACR  
REVIEW** 3-8 NOVIEMBRE 2017  
**SANDIEGO**  
ACR-REVIEW.SER.ES



## ESPONDILOARTROPATÍAS

Dr. Julio Ramírez García



**ACR  
REVIEW** 3-8 NOVIEMBRE 2017  
**SANDIEGO**  
ACR-REVIEW.SER.ES



Bloque 1: Caracterización de los  
pacientes con SpA axial



**ABSTRACT NUMBER: 1509**

**Similarities and Differences between Non-Radiographic and Radiographic Axial Spondyloarthritis**

*Denis Poddubnyy*


- PROOF is a prospective observational study of axSpA pts in clinical practice in 29 countries.
- Of the 2126 pts enrolled in PROOF, 1281 (60.3%) pts were classified as AS and 845 (39.7%) as nr-axSpA
- AS pts expectedly had longer symptom duration, higher CRP and were more often male and treated with TNF-i.
- HLA-B27 + was more frequent among AS pts
- Nr-axSpA had a significantly higher prevalence of enthesitis, psoriasis, and IBD
- BASDAI was significantly higher in the nr-axSpA subgroup

## ABSTRACT NUMBER: 1520

# Golimumab Retention Rate in Patients with Spondyloarthritis. Differences between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

*Belen Serrano*

- ▶ 105 patients were included:
  - ▶ 49 (46.7%) AS
  - ▶ 40 (38.1%) nr-AxSpA
  - ▶ 16 (15,2%) peripheral SpA



## ABSTRACT NUMBER: 1527

### Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?

*Atul A. Deodhar*

- ▶ Retrospective cohort study using three commercial insurance claims databases
- ▶ **Results:** Out of nearly 40 million beneficiaries, 63,052 patients were included.
- ▶ Despite the possibility of patients with **more severe disease receiving TNFi treatment, their crude incidence of certain cardiac, pulmonary and neurologic comorbidities was lower compared to those treated with NSAIDs or DMARDs alone, although they had higher incidence of some EAMs.**



**ACR  
REVIEW** 3-8 NOVIEMBRE 2017  
**SANDIEGO**  
ACR-REVIEW.SER.ES




Bloque 2: Estudios de extensión en SpA

## ABSTRACT NUMBER: 1523

# Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies

*Jürgen Braun*

Figure. Improvement in ASAS40 Response Rate in Patients with Normal/Elevated CRP at Baseline through Week 156





## ABSTRACT NUMBER: 1539

### High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study

*Alan J. Kivitz*

- ▶ **Aim:** Efficacy and safety of secukinumab **over 3 years** from the study MEASURE 2.
- ▶ **Methods:** 219 patients (pts) with active AS were randomized to subcutaneous secukinumab 150 mg (72 pts), 75 mg (73 pts) or placebo (PBO, 74 pts) at baseline.
- ▶ **Results:** Secukinumab 150 mg provided sustained response in the signs and symptoms along with physical function through 3 years in pts with AS, with **over 80% retention rate**.

ABSTRACT NUMBER: 1526

Shift Analysis of Spinal Radiographic Progression after 2 Years of Secukinumab in Ankylosing Spondylitis – Detailed Results from a Phase 3 Trial

*Xenofon Baraliakos*

- ▶ MEASURE 1 trial patients received subcutaneous SEC 75mg or 150mg or placebo (PBO) every 4 weeks up to 2 years.
- ▶ A total of **4947 VE could be analyzed. No mSASSS change to Wk104 was seen in 4891/4947 (98.9%) VEs**, mSASSS increase in 46/4947 (0.9%) VEs and mSASSS decreased in 10/4947 (0.2%) VEs.
- ▶ **This analysis shows that the radiographic status remained stable in almost 99% of VEs in secukinumab-treated patients.**




**ACR  
REVIEW** 3-8 NOVIEMBRE 2017  
**SANDIEGO**  
ACR-REVIEW.SER.ES

## Bloque 3: Estudios Comparativos entre biológicos

## ABSTRACT NUMBER: 1546

# Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data

*Walter P. Maksymowych*






## ABSTRACT NUMBER: 1561

# Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Biologic-Naïve Psoriatic Arthritis

*Vibeke Strand*





**ACR  
REVIEW** 3-8 NOVIEMBRE 2017  
**SANDIEGO**  
ACR-REVIEW.SER.ES

Bloque 4: Abstracts más relevantes

**ABSTRACT NUMBER: 1827**

**Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Data from a Phase 3 Trial**

*Pierre-Dominique Ghislain*

- ▶ **Methods:** Phase 3b, multicenter, randomized, double-blinded, parallel-group trial (IXORA). HEAD TO HEAD
- ▶ Pts with moderate-to-severe plaque psoriasis were randomized (1:1) to receive either IXE (N=136) or UST (N=166).
- ▶ **Results:** At week 12, a significantly higher proportion of patients treated with IXE achieved PASI 90 relative to UST (72.8% [n=99] vs 42.2% [n=70],  $p < 0.001$ , respectively), thereby achieving the primary endpoint of IXORA-S.

## ABSTRACT NUMBER: 1827

NAPSI=0 at **Week 16**,

26 **(31.0%)** IXE-treated patients

18 **(17.1%)** UST-treated patients **(p=0.037)**

NAPSI=0 At **Week 24**

41 **(48.8%)** IXE

24 **(22.9%)** UST **(p=0.012)**

- **Conclusion:** Complete resolution of nail psoriasis was seen in significantly greater percentages of patients treated with IXE compared to UST at Week 24, even though improvement was observed in both groups over 24 weeks.



**ABSTRACT NUMBER: 1787**

**Efficacy and Safety of continuing Versus Withdrawing ADA in Maintaining Remission in patients With Non-Rx-AxSPA**

*Robert Landewé*

➤ **ABILITY-3**

- Pts with ASDAS inactive disease with open-label ADA at week 16, 20, 24 and 28 were randomized to 40-week placebo (blinded) or ADA
- **Results:** of 673 pts, 305 (45%) were randomized
  - At week 68,
  - 70% ADA No flares
  - 47% Placebo (p 0.001)

# ACR REVIEW 3-8 NOVIEMBRE 2017 SANDIEGO

ACR-REVIEW.SER.ES



Bloque 5: Estudios de imagen en SpA

## ABSTRACT NUMBER: 1831

# A Positive MRI of the Sacroiliac Joints Is Not Specific for Axial Spondyloarthritis but Frequently Occurs in Healthy Individuals

*Janneke de Winter (Robert Landewé oral presenter)*

- **Purpose:** To compare MRI-SI of healthy individuals and those with known mechanical strain acting upon SIJ.

